Harold Bernstein Sells 4,432 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 4,432 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $40.43, for a total value of $179,185.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Harold Bernstein also recently made the following trade(s):

• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.00, for a total transaction of $16,480.00.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00.

Maze Therapeutics Trading Up 5.2%

Maze Therapeutics stock opened at $40.37 on Thursday. Maze Therapeutics, Inc. has a 12-month low of $6.71 and a 12-month high of $43.29. The firm has a 50-day moving average price of $37.46 and a 200-day moving average price of $25.55. The firm has a market capitalization of $1.94 billion and a PE ratio of -1.93.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on MAZE shares. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Guggenheim reiterated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Friday, December 19th. Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They set an “overweight” rating and a $55.00 target price for the company. Raymond James Financial began coverage on shares of Maze Therapeutics in a report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price target on the stock. Finally, Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $43.38.

Hedge Funds Weigh In On Maze Therapeutics

Several institutional investors have recently made changes to their positions in the company. Invesco Ltd. purchased a new stake in shares of Maze Therapeutics in the 1st quarter worth approximately $226,000. Goldman Sachs Group Inc. bought a new position in Maze Therapeutics in the first quarter worth approximately $145,000. Ensign Peak Advisors Inc purchased a new stake in Maze Therapeutics during the second quarter worth $227,000. Frazier Life Sciences Management L.P. boosted its position in Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after acquiring an additional 438,274 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of Maze Therapeutics in the 1st quarter valued at $125,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.